Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Pulse Biosciences Appoints Mitchell Levinson to Board of Directors


Pulse Biosciences, Inc.(NASDAQ:PLSE) ("Pulse Biosciences" or the
"Company"), a novel medical therapy company bringing to market its
proprietary CellFX™ System, today announced the appointment of Mitchell
Levinson to its board of directors. In connection with his appointment
to the board, Mr. Levinson will also serve as a member of the audit

"Mitch is an ideal addition to our Board because of his considerable
expertise in developing and bringing revolutionary new products to the
aesthetic dermatology market," said Darrin Uecker, President and Chief
Executive Officer. "His experience will be a significant asset as we are
working to introduce our CellFX System into this market later in 2019."

Levinson, 58, has more than 25 years of experience bringing novel
medical technologies to the market, including over a decade in the
aesthetics procedure market. Levinson previously founded and served as
CEO and CSO of Zeltiq Aesthetics from 2005 to 2010 overseeing the
development and facilitating the early commercial launch of its flagship
CoolSculpting procedure. Prior to Zeltiq, he served as the initial Vice
President of Research and Development for Thermage from 2000 to 2005
where he built the R&D organization and led the development of
Thermage's novel skin tightening technology. Mr. Levinson is currently a
board member and Chief Technology Officer of Cerebrotech, an innovative
neurotechnology device company focused on the development of portable
neurotechnology solutions, that he founded during 2010.

Levinson previously served on the Pulse Biosciences board from January
2015 to November 2017, during which time the Company conducted its
initial public offering and commenced clinical studies. He also
currently serves on the board of directors of ConnectWell, a
leading-edge provider of digital health and wellness content.

Mr. Levinson earned his BS in Mechanical Engineering from University of
California at San Diego, holds an M.S. in Computer Systems from the
University of Phoenix, and is inventor on 45 issued U.S. patents.

About Pulse Biosciences

Pulse Biosciences is a novel medical therapy company bringing to market
its proprietary CellFX™ System. The Company's novel CellFX System
provides a precise, non-thermal delivery of nanosecond duration energy
pulses that impact cells in treated tissue while sparing non-cellular
tissue. This unique mechanism of action disrupts the functions of
internal cell structures while maintaining the outer cell membrane,
initiating a cascade of events within the cell that results in regulated
cell death. The novel characteristics of the Company's CellFX System has
the potential to significantly benefit patients across multiple medical
applications, including dermatology, the Company's first planned
commercial application. In pre-clinical studies, Nano-Pulse Stimulation™
(NPS™) technology platform has demonstrated an ability to induce
immunogenic cell death in several cancer cell lines. The Company
believes its NPS technology platform may play a role in immuno-oncology
as a focal tumor treatment that can initiate an adaptive immune
response. More information can be found at

Forward-Looking Statements

All statements in this press release that are not historical are
forward-looking statements, including, among other things, statements
relating to or implying Pulse Biosciences' timing of bringing the
CellFX™ System to market and other future events. These statements are
not historical facts but rather are based on Pulse Biosciences' current
expectations, estimates, and projections regarding Pulse Biosciences'
business, operations and other similar or related factors. You should
not place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, and assumptions that are
difficult or impossible to predict and, in some cases, beyond Pulse
Biosciences' control. Actual results may differ materially from those in
the forward-looking statements as a result of a number of factors,
including those described in Pulse Biosciences' filings with
the Securities and Exchange Commission. Pulse Biosciences undertakes no
obligation to revise or update information in this release to reflect
events or circumstances in the future, even if new information becomes

CAUTION: Pulse Biosciences' CellFX System and Nano-Pulse
Stimulation (NPS) are for investigational use only.

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial